Cargando…
Safety and Efficacy of a New Ultrathin Sirolimus-Eluting Stent with Abluminal Biodegradable Polymer in Real-World Practice
BACKGROUND AND OBJECTIVES: Recently, Genoss drug-eluting stent (DES)™ stent comprising cobalt-chromium platform with an ultrathin strut thickness, sirolimus, and an abluminal biodegradable polymer was developed. Owing to the lack of substantial evidence for the safety and efficacy of this stent, we...
Autores principales: | Youn, Young Jin, Yoo, Sang-Yong, Lee, Jun-Won, Ahn, Sung Gyun, Lee, Seung-Hwan, Yoon, Junghan, Park, Jae Hyoung, Choi, Woong Gil, Cho, Sungsoo, Lim, Sang-Wook, Jang, Yang Soo, Kwon, Ki Hwan, Lee, Nam Ho, Doh, Joon Hyung, Kang, Woong Chol, Jeon, Dong Woon, Lee, Bong-Ki, Heo, Jung Ho, Hong, Bum-Kee, Choi, Hyun-Hee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Cardiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067606/ https://www.ncbi.nlm.nih.gov/pubmed/31960640 http://dx.doi.org/10.4070/kcj.2019.0258 |
Ejemplares similares
-
Five-year clinical outcomes of the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer
por: Seo, Kyoung-Woo, et al.
Publicado: (2021) -
Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable Polymer
por: Yang, Hyoung-Mo, et al.
Publicado: (2017) -
Clinical safety and effectiveness of the Genoss drug-eluting stent in real-world clinical practice
por: Youn, Young Jin, et al.
Publicado: (2023) -
Safety of 3‐Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus‐Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART‐CHOICE Trial
por: Yun, Kyeong Ho, et al.
Publicado: (2020) -
Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents: Nine months angiographic and 5-year clinical outcomes
por: Zhang, Haijun, et al.
Publicado: (2016)